By Fineline Cube 
China-based genomics testing company Berry Genomics (SHE: 000710) has entered into a project achievement translation cooperation agreement with Beijing Children’s Hospital, Capital Medical University. This collaboration focuses on advancing the early screening and diagnosis of functional birth defects in newborns through the integration of innovative genomics testing and artificial intelligence (AI) technologies.
Project Background and Objectives
The collaboration is centered around the research project titled “Key Technologies and Product Development for Early Screening and Diagnosis of Functional Birth Defects in Newborns” (Project No.: Z221100007422017). Funded by the Beijing Municipal Science & Technology Commission and the Administrative Committee of Zhongguancun Science Park, the project aims to develop and translate early screening technologies into practical applications, enhancing the management of neonatal health.
Technological Advancements and Commercialization
Berry Genomics and Beijing Children’s Hospital will jointly promote the commercialization of technological achievements derived from the “Integrated Pediatric Genetic Disease Platform V1.0.” This platform leverages AI and other advanced technologies to extend services such as genetic counseling, health management, and preventive intervention from newborn screening into childhood. The goal is to establish a full-life-cycle health management system covering fetuses, newborns, infants, and preschool children.
Market and Clinical Impact
The initiative seeks to create a replicable and scalable regional child health management model with significant clinical value and market competitiveness. By integrating genomics testing with AI-driven health management, the collaboration aims to set new standards in pediatric care and prevention, offering a comprehensive solution for early intervention and long-term health monitoring.-Fineline Info & Tech